Studies on the chaperone protein α-hemoglobin stabilizing protein (AHSP) reveal that abundant AHSP in erythroid cells enhance the cells' tolerance to oxidative stress imposed by excess α-hemoglobin in pathological conditions. However, the potential intracellular modulation of AHSP expression itself in response to oxidative stress is still unknown. The present study examined the effect and molecular mechanism of STAT3, an oxidative regulator, on the expression of AHSP. AHSP expression increased in K562 cells upon cytokine IL-6-induced STAT3 activation and decreased in STAT3 knock-down K562 cells. Regulation of AHSP in oxidative circumstance was then examined in α-globin-overloaded K562 cells, and real-time PCR showed strengthened expression of both AHSP and STAT3. ChIP analysis showed binding of STAT3 to AHSP promoter and binding was significantly augmented with IL6 stimulation and upon α-globin overexpression. Dual luciferase reporter assays of the wildtype and mutated SB3 element, an IL-6RE site, in the AHSP promoter in K562 cells highlighted the direct regulatory effect of STAT3 on AHSP gene. Finally, direct binding of STAT3 to SB3 site of AHSP promoter was confirmed with EMSA assays. Our work reveals an adaptive AHSP regulation mediated by the redox-sensitive STAT3 signaling pathway, and provides clues to the therapeutic strategy for AHSP enhancement.
Unbalanced globin chain synthesis exposes and sensitizes erythroid cells to oxidative stress. The newly defined α-hemoglobin stabilizing protein (AHSP) is necessary for free α-globin stabilization and hemoglobin tetramer assembly [1,2], which guards against the threat imposed by free α-Hb. The interaction between AHSP and α-Hb converts the latter into a non-reactive, hexacoordinate ferric form and prevents its damaging effects as a pro-oxidant in vivo, underlying the protective role of AHSP in the redox equilibrium of erythroid cells [3, 4] . However, how AHSP itself is regulated under oxidative stress has been largely unknown.
As critical signaling molecules under oxidative circumstances, reactive oxygen species (ROS) mediate distinct responses to oxidative stress through various pathways [5, 6] . Signal transducers and activators of transcription (STAT) proteins are a group of important redox regulated effectors [7] that play important roles in regulating hematopoietic homeostasis [8] . STATs can be activated by ROS production in response to the stimulation of cytokines or growth factors, during which STATs are recruited to their cognate receptors and phosphorylated at distinct tyrosine residues by the Janus family of kinases (JAKs) or Src kinases. Activated STATs then homo-or heterodimerize and translocate to the nucleus, initiating a cytoprotective process via modulating the expression of a panel of antioxidant genes or apoptotic genes, and participating in the regulation of cell survival, proliferation and maturation [9, 10] . STAT3 is a major member of the STATs and is phosphorylated at Tyr705 and Ser727 sites upon activation [11] . Constitutive STAT3 phosphorylation exhibits oncogenic properties in promoting cell survival [12] , and IL6 (interleukin 6)-gp130-STAT3-dependent gene activations have been demonstrated to confer cyto-protection in distinct tissues [13, 14] .
In this report, we identified the AHSP gene as a STAT3 target. Overloading -globins in K562 cells activates STAT3 and promotes AHSP gene expression. Multiple STAT3 binding sites were detected in the AHSP promoter, among which the SB3 site constitutes a key STAT3 regulating element bordered by a Nrf2/ARE element. Mutation of the consensus cAMP responsive element (CRE) within the Nrf2/ARE element of the SB3 site dramatically decreased STAT3 transactivity on the AHSP promoter and abolished direct binding of STAT3 to the SB3 site.
Materials and methods

Cell culture and drug treatment
Recombinant IL-6 (SRP3096) was purchased from SigmaAldrich (USA). For IL-6 stimulation, human chronic myelogenous leukemia K562 cells were collected and resuspended in serum free RPMI 1640 medium and treated with IL-6 (100 ng mL 1 ) for 2 h. The human α-globin (HBA) over-expressing K562 stable line was cultured in RPMI 1640 medium containing 10% fetal bovine serum, and human embryonic kidney 293T cells were maintained in Dulbecco's modified Eagle's medium (high sugar) supplemented with 10% fetal bovine serum.
Plasmid construction and transfection
For generation of over-expression plasmids, the coding sequences of STAT3 and α-globin were cloned into pcDNA3.1() and pcDNA3.1(+) respectively. STAT3 was knocked down using hairpin RNA directed against the sequence 5′-GCGTCCAGTTCACTACTAA-3′, and the oligonucleotides encoding shRNAs were ligated into an RNAi-ready pSIREN-RetroQ vector (Clontech, USA). The resulting STAT3 knock-down K562 cells were generated by retrovirus-mediated RNAi. The pRetroQ-siGFP (5′-GCAAGCTGACCCTGAAGTT-3′) vector was used as control. The HBA stable line (HBA-K562) and control cells were obtained by transfecting K562 cells with pCDNA3.1-HBA-myc and empty vector respectively, using Lipofectamine 2000 (Invitrogen, USA).
RNA extraction and real-time qRT-PCR
Total RNA was extracted from differentially treated K562 cells using Trizol (Invitrogen) according to the manufacturer's instructions. First-strand cDNA was synthesized with M-MLV Reverse Transcriptase and random primer (New England Biolabs, USA). Real-time qPCR experiments were performed using the iQTM5 Real-Time PCR Detection System (Bio-Rad, USA) and SYBRGreen PCR Mix (TaKaRa, Japan). Primer pairs were as follows: AHSP amplication sense 5′-TGATCCTCTCGTCTGAAGAAGAC-3′ and antisense 5′-GCTGCCTGTAATAGTTGATGTAGA-AGT-3′; and STAT3 amplification: sense 5′-ACCTGCA-GCAATACCATTGAC-3′ and antisense 5′-AAGGTGAG-GGACTCAAACTGC-3′. AHSP and STAT3 expression levels were quantified by normalizing against the internal control β-actin (sense 5′-GGACATCCGCAAAGACCTGTAC-3′ and antisense 5′-AGGAGGAGCAATGATCTTGATC-TT-3′) using the delta Ct method.
Western blotting
The STAT3 knock-down k562 cells were collected and lysed in RIPA buffer (NP-40 0.1%, NaCl 150 µmol L 1 ,
DTT 100 µg mL 1 , PMSF 100 µg mL 1 and Protease Inhibitor Cocktail, pH 8.0). Samples were quantified with a Pierce BCA protein assay kit, separated on a 15% SDS-PAGE gel and transferred to PVDF membranes. The membranes were then incubated overnight with monoclonal anti-STAT3 (D372G), anti-phospho-STAT3 (Tyr705) from Cell Signaling Technology (USA) or polyclonal anti-GAPDH (FL-335) from Santa Cruz Biotechnology (USA), followed by incubation with corresponding secondary antibodies for approximately 1-2 h at room temperature. The HBA-K562 stable line was identified with anti-c-Myc (9E10) monoclonal antibodies from Santa Cruz Biotechnology; anti-actin (AC-15) was obtained from Sigma. Bands were visualized with the ECL chemiluminescence kit (Vigorous, China). Human AHSP anti-serum was noncommercial and generously provided by Dr. Weiss (Children's Hospital of Philadelphia, USA).
Reporter plasmid construction and luciferase reporter assay
The AHSP promoter reporter plasmid (AHSP-Luc) was constructed by PCR amplification of the 1.1 kilobase region (912 to +254 bp) surrounding AHSP gene transcriptional start site and inserting the PCR product into the MluI/XhoI sites of pGL3-Basic vector (Promega, USA). SB3 reporter plasmids (SB3-Luc or SB3-mut) were constructed by annealing synthesized DNA oligos containing the wild type or mutant STAT3 binding site (95 to 36 bp) with flanking MluI/XhoI sites, and inserting the resulting double-strand DNA into the pGL3-Enhancer vector (Promega). HEK293T cells were transfected at 50% confluence using VigoFect according to the manufacturer's instructions (Vigorous). Cells were harvested 48 h later. Luciferase activity was measured with the Dual Luciferase Reporter Assay System Kit (Promega) and detected in a LB960 Microplate Luminometer (Berthold, Germany). Data were collected in at least three separate experiments. The statistical significance test was used to analyze the results.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) analysis of control, IL-6 treated and α-globin-overloaded K562 cells was performed as previously described with minor modifications [15] . The precleared cell lysates were immunoprecipitated individually with 4 µg of anti-STAT3 (D372G), antiphospho-STAT3 (Tyr705), anti-phospho-STAT3 (Ser727) primary antibodies (Cell Signaling Technology) or 10 µL (4 µg) normal rabbit IgG (Santa Cruz). Precipitated DNA was dissolved in 100 µL ddH 2 O and analyzed by real-time qPCR using the iQTM5 Real-Time PCR Detection System (Bio-rad) and SYBRGreen PCR Mix (TaKaRa) or by semi-quantitative PCR. PCR primers are listed in Table 1 .
The Y-axis of the quantitative ChIP results is shown as relative enrichment of immunoprecipitated DNA to input. The 5′-UTR of the gamma-globin gene was used as a positive control for STAT3 binding [16] and the promoter of the brain-specific necdin gene served as a negative control.
Electrophoretic mobility shift assay
Nuclear extracts were prepared from electrophile tBHQ (tert-butylhydroquinone) treated (20 µmol L 1 , 6 h) and control K562 cells as described [17] . EMSA analysis was performed using a LightShift Chemiluminescent EMSA Kit (Pierce, USA) according to the manufacturer's instructions. Each reaction contained 20 µL volume including 8 µg nuclear extract and 20 nmol L 1 labeled and annealed SB3 probe (forward: biotin-5′-TCTCCTCCCTAGAATGACCT-ATCACCCTCCTTCAGGACCT-3′ and reverse: biotin-5′-AGGTCCTGAAGGAGGGTGATAGGTCATTCTAGG GAGGAGA-3′) or mutant SB3 probe in which the mutations are shown in lowercase letters (forward: biotin-5′-TCTCCTCCCTAGAagacCCTAcagCCCTCCTTCAGG-ACCT-3′ and reverse: biotin-5′-AGGTCCTGAAGGAGGGctgTAGTgtcTTCTAGGGAGGAGA-3′). Nrf2 (4 µg) antibody was used in supershift assays, and 150-fold molar excess unlabeled IL-6RE probes (repeated TTCTGGGAA) containing canonic STAT3 binding sequence were pre-incubated in competition experiments. Reaction mixtures were fractionated on non-denaturing 6% polyacrylamide gels and transferred to a nylon membrane. The DNA was cross-linked to the membrane by UV-light at 150 mJ cm 2 and the membrane was exposed to X-ray film and developed.
Results
AHSP is a target gene of STAT3
STAT3 is one of the key regulators in the ability of hematopoietic cells to cope with oxidative stress [18] . To examine whether the α-globin chaperone AHSP is a target gene of STAT3 signaling in redox equilibrium of erythroid cells, we first used cytokine IL-6 as a STAT3 signaling inducer to treat the chronic myelogenous leukemia K562 cell line and detected enhanced AHSP expression after IL-6 treatment ( Figure 1A and B) . Conversely, knockdown of STAT3 in K562 cells with pSIREN-RetroQ retrovirus expressing short hairpin RNA against STAT3 led to decreased STAT3 as well as AHSP expression at both the mRNA level ( Figure  1C ) and protein level ( Figure 1D ). Simultaneous upregulation of STAT3 and AHSP genes were observed in K562 cells overloaded with α-globin (HBA-K562), which to some degree mimics the pathologically oxidative environment of β-thalassemia ( Figure 1E and F) . These results collectively suggest that STAT3 is a regulator of AHSP gene expression, and implied that AHSP could be targeted by STAT3 in response to oxidative stress in erythroid cells.
STAT3 binds to and activates AHSP promoter
To further explore the regulatory mechanisms through which STAT3 may regulate AHSP expression, we investigated the direct occupancy of STAT3 at the promoter of AHSP in K562 cells. STAT family proteins generally recognize a consensus DNA binding motif of TTCC (C or G) GGAA (or generically TTN5AA) [19] . Three putative STAT3 binding sites (SB), named SB1 to SB3, were predicted in the AHSP promoter (Figure 2A ). ChIP analyses were performed to detect the binding of total STAT3 and its active forms, Tyr705 and Ser727 phosphorylated STAT3 (pSTAT3-Tyr705 and pSTAT3-Ser727), at the putative binding sites. In untreated K562 cells, weak binding of STAT3 was detected at the SB1 site, and no binding of either active form of STAT3 was detected. After 2 h treatment with IL-6 (100 ng mL 1 ), which activates the STAT3 signaling pathway, intense binding of STAT3 was found at SB2 and the pSTAT3-Tyr705 signal became detectable at both SB2 and SB3 sites, while the signal for pSTAT3-Ser727 remained undetectable ( Figure 2B ). We next examined STAT3 binding status in α-globinoverloaded K562 cells. Similar to IL6-induced cells, STAT3 was observed to bind to SB2, while pSTAT3-Tyr705was specifically detected at the SB3 site ( Figure 2C ). No obvious pSTAT3-Ser727 signal was detected.
To examine the transactivity of STAT3 on the AHSP promoter, which contains SB2 and SB3, we established a luciferase reporter construct by inserting the AHSP promoter sequence (912 to +254 bp) into the pGL3-basic vector (AHSP-Luc). The empty pGL3-basic vector was used as a negative control. Co-expression of STAT3 in HEK293T cells stimulated the activity of AHSP-Luc by nearly 6-fold compared with ASHP-Luc alone, suggesting that STAT3 regulates AHSP expression by targeting its promoter ( Figure 2D ). 
The SB3 element is a critical site for STAT3 binding and activation of AHSP promoter
In both IL6-induced and α-globin-overloaded K562 cells, pSTAT3-Tyr705, the active form of STAT3 was found to strongly bind to the SB3 element (167 to 21 bp) upstream of the AHSP transcriptional initiation site. Analysis of the SB3 sequence revealed an atypical STAT3/IL-6RE binding site TCCCTAGAA bordered by a cAMP responsive element (CRE)-like element within an atypical Nrf2/ARE site ( Figure 3A) . The CRE element has been shown to be necessary for STAT3 function in regulating JunB [20] and STAT3 itself [21] . The luciferase activity of the SB3 reporter (SB3-Luc) was induced by approximately 6-fold with stimulation of STAT3 compared with SB3-Luc alone (Figure 3B) . Mutation of TGAC...TCA in the CRE element to GACC…CAG almost completely offset the STAT3 effect ( Figure 3B ), suggesting the dependency of STAT3 activity on the proximal CRE element. Direct binding of STAT3 to SB3 element was determined in EMSA analysis ( Figure 3C ). Two shifted bands were observed with a probe containing the SB3 element, both of which were strengthened with nuclear extracts from Figure 3 The SB3 element is directly targeted and activated by STAT3. A, Sequence analysis of SB3 in the AHSP proximal promoter. An atypical STAT3 binding site (black capitals) juxtaposed to a putative Nrf2 binding site (underlined) is found in the −61 to −75 bp region of SB3. Consensus CRE-like element (gray box) is shown embedded in the putative Nrf2 binding element. B, Dual luciferase reporter analysis of STAT3 trans-activity on SB3 element in HEK 293T cells. Mutation of the consensus CRE-like element (labeled with stars) eliminated STAT3 transactivation via the SB3 element. **, P<0.01. C, EMSA analysis of the SB3 probe with nuclear extracts from tBHQ treated and control K562 cells. Note that the lower band was specifically supershifted by Nrf2 antibody. Mutation of the CRE-like element had no effect on the lower band, but resulted in the disappearance of the top band, which was completely competed by 150-fold molar excess of the cold IL-6RE probe.
tBHQ-treated K562 cells. The lower band was identified as a Nrf2 shift as it was specifically supershifted by Nrf2 antibody. Introduction of the CRE mutation into the SB3 probe resulted in the alleviation of the top shifted band, addition of 150-fold molar excess of cold IL6-RE probe completely competed the shift band away. These observations confirmed the binding of STAT3 on the top band and indicated that the CRE mutation disrupted the binding of STAT3 to the SB3 element.
Discussion
AHSP is a unique chaperone molecule involved in hemoglobin subunit stabilization and assembly. Lineage specific AHSP expression, like that of many other erythroid specific genes, has been attributed to the master erythroid transcription factors including GATA1, EKLF, and NFE2P45 [22, 23] . In this study, we show that AHSP expression is directly modulated by STAT3 signaling. We characterized the binding pattern of STAT3 to the AHSP promoter upon IL6 induction and α-globin overloading in K562 cells. Furthermore, the CRE element proximal to the STAT3 consensus sequence in the SB3 site of the AHSP promoter was found critical for the binding and activity of STAT3. Our work provides the first evidence for the dynamic regulation of AHSP expression by a cell signaling pathway and implies that AHSP may be an active responder to oxidative stress.
Cytokine IL-6, in combination with multiple factors, is reported to act in the early stage of erythropoiesis [24] . STAT3 is a well-known downstream effector of IL-6 signaling in acute-phase response regulation [25] . It is also shown to be required for erythropoietin receptor dependent regulation of red blood cell development [26] . A recent study claimed that cell-targeted deletion of the STAT3 gene in hematopoietic stem cells/hematopoietic progenitor cells results in excessive ROS production and shortened cell life span [27] . In addition, significant upregulation of STAT3 is found to accompany extramedullary stress erythropoiesis [28] , and constitutive STAT3 activation by IL6 has been found in polycythemia vera patients [29] . We show that a 2 h induction with IL-6 stimulates the binding of pSTAT3-Tyr705 to the AHSP promoter and augments AHSP expression in K562 cells, meanwhile, AHSP levels were reduced in STAT3-siRNA K562 cells. Moreover, a concomitant increase of AHSP as well as STAT3 transcription was observed in α-globin-overloaded K562 cells. Together, these observations propose AHSP as a new target of STAT3 signaling for orchestrating cellular homeostasis under stress conditions during erythropoiesis. AHSP gene expression was previously reported to increase parallel to α-globin during maturation of erythroid cells [30] . The potential involvement of STAT3 remains an intriguing issue to be investigated in primary erythroid cultures or during embryonic hematopoiesis.
Multiple STAT3 binding sites were identified in the AHSP promoter. Although STAT3 knock-down K562 cells showed decreased AHSP expression, the binding of STAT3 in unchallenged K562 cell was weak. Remarkable STAT3 binding was observed after the stimulation by IL-6 or overwhelming free α-globin, indicating those sites as predominantly stress-responsive elements. In addition, pSTAT3-Tyr705, but not pSTAT3-Ser727 signals, were detected in both IL-6 treated and α-globin-overloaded K562 cells, suggesting divergent functions of these two active STAT3 modifications. The observations are consistent with a previous study which claims that p-STAT3-Tyr705 is necessary for STAT3 activation, while p-STAT3-Ser727 may be asscociated with stronger transactivation [31] .
We show that the STAT3 binding site at SB3 is one of the major STAT3 responsive elements in the AHSP promoter. In addition, the SB3 site contains an atypical Nrf2/ARE element intimately connected with the STAT3 site. In addition to the binding of STAT3, EMSA analysis also showed the in vitro binding ability of Nrf2 to SB3. Nrf2 is the central mediator of ROS signaling [32] and has been shown important for maintaining redox balance in hemolyte anemia [33] . Nrf2 also regulates heme synthesis, iron transportation and globin gene expression in erythroid cells [34, 35] . We found in this work that the Nrf2 activator tBHQ-treated K562 cells nuclear extract displayed apparent increased STAT3-binding to the SB3 site in EMSA. This observation is consistent with the previous study showing that Nrf2 controls the expression of IL-6, which is upstream of STAT3 signaling [36] . Alternatively, this might indicate a potential synergy between Nrf2 and STAT3 when recruiting to target sites in the AHSP promoter. Further investigation of the Nrf2/ARE pathway is therefore necessary for corroborating this promising new candidate in AHSP gene regulation and teasing out the potential cross-talk between Nrf2 and STAT3 in AHSP regulation. Furthermore, how the anti-oxidative response elements, such as the SB3 site identified in this study, may cooperate with the erythroid specific cis-elements [37] in coordinating AHSP expression remains an intriguing issue to be investigated in thalassemia cells.
